Navigation Links
Study raises questions about prostate cancer therapies targeting IGF-1
Date:4/30/2008

SEATTLE Therapies under development to treat prostate cancer by inhibiting the ability of insulin-like growth factor (IGF-1) to activate its target receptor could have unexpected results especially if a major tumor suppressor gene p53 is already compromised, according to new research by investigators at Fred Hutchinson Cancer Research Center.

IGF-1 is a polypeptide hormone that can influence growth, differentiation and survival of cells expressing the type 1 receptor (IGF-1R). Past clinical, epidemiological and experimental studies have strongly implicated IGF-1 as a contributing factor in the natural history of prostate cancer. However, very little has been done to prove absolutely that the expression or activation of the IGF-1 signaling pathway at physiologically relevant levels is sufficient to cause a healthy prostate cell to become a cancer cell.

Norman Greenberg, Ph.D., and colleagues conducted a pair of experiments by manipulating gene expression directly in the epithelial compartment of the mouse prostate gland to better understand the role of IGF-1R. In contrast to studies that correlated elevated levels of IGF-1 with the risk of developing prostate cancer, Greenbergs research showed that eliminating IGF-1R expression in an otherwise normal mouse prostate caused the cells to proliferate and become hyperplastic. Although persistent loss of IGF-1R expression ultimately induced cell stasis and death, both of these processes are regulated by the tumor suppressor gene p53 that is commonly mutated in human prostate cancers. Hence the researchers hypothesized that tumors with compromised p53 might not respond predictably to therapies targeting IGF1 signaling.

To test their reasoning they conducted a second experiment by crossing mice carrying the prostate-specific IGF-1R knockout alleles with transgenic mice that develop spontaneous prostate cancer when p53 and select other genes are compromised. The results were as predicted: Pro
'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Children More Vulnerable to Harmful Effects of Lead at Age 6 Than as Toddlers, Says New Study
2. Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers
3. Penn study finds elderly heart patients with ICD devices live longer after heart failure
4. Physical activity, healthy eating and BMI not linked in older teens: study
5. Salk study links diabetes and Alzheimers disease
6. U of M study: Online intervention paramount for reducing HIV in high-risk population
7. Study Reveals Women Feeling Growing Financial Pressures on Family Life
8. Experimental Blood Substitutes Unsafe, Study Finds
9. Spinal cord injury research hampered by animal models, says new study
10. Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted
11. Kaiser Permanente study finds diabetes doubling before motherhood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2008)...f paperless prescription use yields practical guid...ans and policy makers, WASHINGTON, MAY 20 /PRNews...ive (eHI) and the Center for Improving Medication ...idely anticipated report detailing the,impact of e...ians,consumers, employers, health plans and polic...
(Date:5/20/2008)...NDIANAPOLIS, May 20 /PRNewswire/ -- On May 25, one...lara Honda, will be racing to win,the Indianapolis...ndness --,Eyes on the Road. By emblazoning their c..., http://www.eyesontheroad.org, IndyCar owners J...nd its driver, IndyCar Series,veteran Tomas Scheck...
(Date:5/20/2008)...ows inhaling long, thin carbon nanotubes may resul... /PRNewswire-USNewswire/ -- A major study publishe...ms of carbon nanotubes -- a,poster child for the "...as,asbestos if inhaled in sufficient quantities., ...ific types of,nanotubes have the potential to caus...
(Date:5/20/2008)...inical settings, DNA microarrays are currently uns... on formalin-fixed paraffin-embedded tissues is re... markers for identifying the prognosis of gastric ...team led by Professor Zhong-Sheng Zhao, is describ...7, 2008 in the World Journal of Gastroenterology. ...
Breaking Medicine News(10 mins):Health News:eHealth Initiative and the Center for Improving Medication Management to Present Report Detailing Both Impact of E-Prescriptions on U.S. Health Care System and Guidelines for Achieving Optimal Results 2Health News:eHealth Initiative and the Center for Improving Medication Management to Present Report Detailing Both Impact of E-Prescriptions on U.S. Health Care System and Guidelines for Achieving Optimal Results 3Health News:Luczo Dragon IndyCar Carries 'Eyes on the Road' Logo to Prevent Blindness to Indy 500 2Health News:Carbon Nanotubes That Look Like Asbestos, Behave Like Asbestos 2Health News:Carbon Nanotubes That Look Like Asbestos, Behave Like Asbestos 3Health News:Carbon Nanotubes That Look Like Asbestos, Behave Like Asbestos 4
...e products Regulatory Agency (MHRA) warned that so...s. The diabetic patients are cautioned about this ...iving readings which were far too high. Diabetes t...e rates are high. This would sometimes lead to pat...
...ucted by researchers it is found that social relat...hurch regularly have a positive affect on older ad...educed stress and the results of the study are pub...search has suggested that greater involvement in r...
... Dr. Jacques P. Tremblay who is in the Human Genet... Universitaire de Québec (CHUQ) // and professor w...cell transplant is one of the important alternativ...s team of researchers conducted the muscle cell tr...
...ivered identical quadruplets, a rarity claimed to ... a corporate hospital here. // Shruthi Vivekanand...the girl babies- Aditi, Aakriti, Akshathi, Aapthi,...t, ten weeks prior to her full term, without any m...
Other Medicine News:Health News:Cure Insight for DMD 2
(Date:5/20/2008)...tended if Patients Receive the Most Ef... May 20 /- Precision Therapeutics Inc...l-based test that examines the,response of a speci...relates with significantly longer overall survival...ients who received a treatment determined by,Chemo...
(Date:5/20/2008)...all/ -- Palatin Technologies,Inc. (Amex: PTN ) a... Phase,2a clinical study of PL-3994, a novel, long... subjects with controlled hypertension., The stud...ll include up,to five cohorts receiving escalating...ith six active subjects and one placebo subject pe...
(Date:5/20/2008)...- Delcath Systems, Inc.,(Nasdaq: DCTH ) announced...,Officer, provided an update on enrollment numbers... today at a gathering of financial and healthcare,...h Annual Global,Healthcare Conference., Mr. Taney... the Phase,III clinical trial of the Company,s Per...
(Date:5/20/2008)...in May 20 Issue of Neurology, WOODCLIFF LAKE, N.J...th,America announced today the publication of a pl...ients with Lennox-Gastaut syndrome (LGS) treated,w...mide as adjunctive,therapy experienced more than 4...lacebo (increase of 1.4%). The differences between...
Breaking Medicine Technology:Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer 2Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer 3Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994 2Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994 3Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited 2Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited 3Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40% 2Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40% 3American Heart Association Honors Regence BlueCross BlueShield of Utah as the States First Start 21 Fit Friendly Company 5802 1American Heart Association Honors Regence BlueCross BlueShield of Utah as the States First Start 21 Fit Friendly Company 5802 2American Heart Association Honors Regence BlueCross BlueShield of Utah as the States First Start 21 Fit Friendly Company 5802 3New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease 803 1New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease 803 2New Anti TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 800 1New Anti TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 800 2New Anti TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 800 3New Anti TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 800 4New Anti TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 800 5New Anti TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 800 6New Anti TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 800 7Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 1731 1Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 1731 2Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 1731 3Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 1731 4Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 1731 5
..., May 21, 2007-The U.S. Food and Drug Administrati...ted to Avandia,(rosiglitazone), a drug approved to...d clinical trials have shown that there is a,poten...ttack and,heart-related deaths in patients taking ...data from long-term clinical trials of,Avandia, in...
...epresented Prescription Pain,Reliever to Health Ca...07-The U.S. Food and Drug,Administration,s (FDA) O...oday that The Purdue Frederick Company, Inc. has a...minal charges and civil,liabilities in connection ...d sell OxyContin, a powerful prescription pain rel...
Other Medicine Technology:FDA Issues Safety Alert on Avandia 2FDA Issues Safety Alert on Avandia 3FDA Announces Results of Investigation Into Illegal Promotion of,OxyContin by The Purdue Frederick Company, Inc. 2
The OX-2 is configured asstandalone or handheld unit, designed for hospital, transport and home use.
The 8600 Series Tabletop/Portable Digital Pulse Oximeter provides a simple universal tool for patient monitering. From transport applications to continuous monitoring, the 8600 has earned the confide
Halogen-free immersion oil based on ester oil.
Immersion oil composed on polyester polyol, diphenyl cresyl phosphate and tricyclodecane dimethanol.
Medicine Products: